Alvotech (NASDAQ:ALVO) and partner Teva Pharmaceuticals (NYSE:TEVA) announced Friday the U.S. Food and Drug Administration (FDA) approval for their arthritis injection, Simlandi (adalimumab-ryvk).
That is because Alvotech and commercial partner Teva have claimed approval for their Simlandi biosimilar of Humira (adalimumab), which includes the first and so far only fully interchangeable ...
Friday, Alvotech (NASDAQ:ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd (NYSE:TEVA), announced the FDA approved Simlandi (adalimumab-ryvk) injection ...
The success of AVT05 builds on recent approvals of other biosimilars, such as SIMLANDI and SELARSDI. ALVO closed Friday's (Jan.24, 2025) trading at $12.99 down 0.99%. TEVA closed Friday's (Jan.24 ...